TrialThe Lancet. Oncology2016

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Jeffrey S Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.